PAWC
SYRE icon

P.A.W. Capital’s Spyre Therapeutics SYRE Stock Holding History

P.A.W. Capital’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,560
Closed -$182K – 61
2020
Q1 		$182K Sell
1,560
-2,440
-61% -$415K 0.25% 59
2019
Q4 		$764K Buy
+4,000
New +$785K 0.81% 28

Other funds holding SYRE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

P.A.W. Capital's SYRE Position: Q2 2020 in Review

P.A.W. Capital sold out of Spyre Therapeutics (SYRE) in Q2 2020, closing a stake of 1,560 shares — an estimated $182K sold.

P.A.W. Capital first reported a position in SYRE in Q4 2019 and held it in 2 quarters. The position peaked at $764K in Q4 2019. 87 funds tracked by Wall St. Rank hold SYRE as of Q2 2020.

  • P.A.W. Capital reported no remaining Spyre Therapeutics position as of Q2 2020 after selling out during the quarter.
  • P.A.W. Capital sold 1,560 Spyre Therapeutics shares in Q2 2020, an estimated $182K.
  • P.A.W. Capital first reported a position in Spyre Therapeutics in Q4 2019 and held it in 2 quarters.
  • P.A.W. Capital's Spyre Therapeutics position peaked at $764K in Q4 2019.
  • 87 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2020.

Based on P.A.W. Capital's 13F filing for Q2 2020, filed 27 Jul 2020.